Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Rivastigmine products are in shortage in Canada (1 of 30 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A medication used to treat symptoms of dementia in Alzheimer's and Parkinson's disease.
Products affected
1 / 30
In shortage since
Jul 29, 2025
Reports on file
92
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MED-RIVASTIGMINE
1.5MG · CAPSULE · GENERIC MEDICAL PARTNERS INC
DIN 02401614 · since Jul 29, 2025, est. end Sep 15, 2025 · Demand increase for the drug.
Resolved
MYLAN-RIVASTIGMINE PATCH 5
4.6MG · PATCH · MYLAN PHARMACEUTICALS ULC
DIN 02423413 · ended Mar 19, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ RIVASTIGMINE PATCH 10
9.5MG · PATCH · SANDOZ CANADA INCORPORATED
DIN 02426307 · ended Feb 2, 2026 · Disruption of the manufacture of the drug.
Resolved
EXELON
2MG · SOLUTION · KNIGHT THERAPEUTICS INC.
DIN 02245240 · ended Dec 10, 2025 · Demand increase for the drug.
Resolved
EXELON
4.5MG · CAPSULE · KNIGHT THERAPEUTICS INC.
DIN 02242117 · ended Nov 10, 2025 · Demand increase for the drug.
Resolved
EXELON
3MG · CAPSULE · KNIGHT THERAPEUTICS INC.
DIN 02242116 · ended Nov 10, 2025 · Demand increase for the drug.
Resolved
EXELON
1.5MG · CAPSULE · KNIGHT THERAPEUTICS INC.
DIN 02242115 · ended Dec 1, 2025 · Demand increase for the drug.
Resolved
JAMP RIVASTIGMINE
1.5MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02485362 · ended Aug 1, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RIVASTIGMINE
4.5MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02485389 · ended Aug 1, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RIVASTIGMINE
4.5MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02485389 · ended Aug 1, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RIVASTIGMINE
3MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02485370 · ended Aug 1, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RIVASTIGMINE
3MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02485370 · ended Aug 1, 2025 · Disruption of the manufacture of the drug.
Showing 12 of 60 reports. All reports are on file with Health Canada.
What's happening
Rivastigmine is currently affected by an active shortage report filed with Health Canada by GENERIC MEDICAL PARTNERS INC.
The reported cause is: demand increase for the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Rivastigmine is classified under “ANTI-DEMENTIA DRUGS” (ATC N06DA).
Recent changes
No changes recorded yet.
Common questions
What is Rivastigmine used for?
A medication used to treat symptoms of dementia in Alzheimer's and Parkinson's disease.
When will Rivastigmine be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Rivastigmine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.